Fused Bicyclic Orexin-2 Agonists for CNS Permeability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compounds with orexin-2 receptor agonist activity are not satisfactory in terms of activity, pharmacokinetics, permeability into the brain/central nervous system, or safety for treating conditions like narcolepsy and other disorders.
Innovation Solution
Development of fused bicyclic compounds represented by Formula I-A or its pharmaceutically acceptable salts, which act as orexin-2 receptor agonists, with specific ring structures and substituents to enhance efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds with orexin-2 receptor agonist activity are used, then some therapeutic effect is achieved, but activity, pharmacokinetics, brain permeability, and safety are not satisfactory
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular structure parameters of orexin-2 receptor agonists. Specific substitutions at defined positions (R1-R11) with various chemical groups (halogens, alkyls, aryls, heteroaryl s) optimize the balance between therapeutic efficacy and safety profile, improving brain permeability and pharmacokinetic properties while maintaining or enhancing receptor activity
2Difficulty of detecting and measuring
If compound structure is modified to improve brain permeability, then permeability into CNS is enhanced, but activity or safety may be compromised
Solution Approach 1:
The patent applies local quality by making specific localized modifications at different positions of the molecular scaffold. Each position (R1 through R11) can be independently substituted with specific chemical groups tailored to optimize local properties such as lipophilicity, hydrogen bonding capacity, and steric bulk, thereby enhancing brain permeability while preserving essential receptor interaction features
Solution Approach 2:
The patent systematically varies molecular parameters including substituent type, size, and position to optimize the relationship between brain permeability and receptor activity. By controlling parameters such as logP, molecular weight, and hydrogen bond donors/acceptors within optimal ranges, the patent achieves enhanced CNS penetration while maintaining therapeutic efficacy
Data Source
AI summary
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.